Bliss GVS Pharma open offer: ₹829 cr at ₹299 in 2026

What was disclosed and why it matters

Bliss GVS Pharma Ltd has been at the centre of a change-of-control process after a share purchase agreement (SPA) signed in May 2026 triggered a mandatory open offer under SEBI’s takeover regulations. SBI Capital Markets Ltd, acting as the manager to the open offer, submitted a post-offer advertisement to BSE for the attention of public shareholders. The disclosure also states that the underlying transaction under the SPA remained unconsummated as per the post-offer advertisement.

For public shareholders, the open offer is the key event because it sets a cash exit route at a fixed price and provides a formal timeline for tendering shares. The open offer parameters, dates, and eligibility rules are laid out through the Draft Letter of Offer and subsequent schedule updates following SEBI’s final observations.

Parties involved in the transaction

The acquirer is Anupam Rasayan India Limited. The offer is being made along with its wholly owned subsidiary, Mates Visa Consultancy Private Limited, designated as a person acting in concert (PAC). Bliss GVS Pharma Ltd is the target company.

SBI Capital Markets Limited has been appointed as the Manager to the Offer. The Draft Letter of Offer was filed with SEBI and was stated to be available on the websites of SEBI and the company.

The trigger: SPA for a 43%+ stake and change of control

According to the provided disclosures, in May 2026 Anupam Rasayan India signed an SPA to acquire 43.30% of Bliss GVS Pharma from promoter and non-promoter shareholders. Another reference in the same context describes the change of control as being triggered by acquisition of a 43.11% stake via an SPA dated May 23, 2026.

This acquisition triggers an open offer obligation under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST), as amended. On closing, Anupam Rasayan is expected to become the new promoter, as stated in the context.

Open offer size, price, and total consideration

The open offer is a cash offer to acquire up to 26.00% of the expanded voting share capital of Bliss GVS Pharma. It covers up to 2,77,26,848 fully paid-up equity shares (face value ₹1 each) at an offer price of ₹299.00 per share.

Assuming full acceptance, the total consideration is ₹829.03 crore (also shown as ₹8,29,03,27,552.00 in the draft details). The offer price is stated to have been determined in accordance with Regulation 8(2) of the SEBI (SAST) Regulations.

Timeline updates after SEBI’s final observations

The offer timeline appears in multiple versions across the draft and later updates. In the draft schedule, the identified date was July 2, 2026, with the tendering period scheduled to open on July 16, 2026 and close on July 29, 2026. The draft also stated August 12, 2026 as the last date for payment of consideration or refund of shares.

Later, Anupam Rasayan India Ltd, alongside its PAC, updated the schedule after SEBI’s final observations. The revised tendering period was set to July 28, 2026 to August 10, 2026. The revised timeline also includes dispatch of the Letter of Offer on July 21, 2026, and payment completion on August 24, 2026.

Identified date and shareholder eligibility

The identified date is used to determine eligible public shareholders for the open offer process. The disclosures note a revision in the identified date from July 2, 2026 to July 14, 2026 in the updated schedule.

At the same time, the text explicitly states that all public shareholders are eligible to participate during the tendering period, including shareholders who acquired shares after the identified date or those who did not receive the Letter of Offer.

Post-offer advertisement and the status of the SPA

On September 2, 2026 (10:08 AM IST), Bliss GVS Pharma disclosed that SBI Capital Markets, the manager to the open offer, submitted to BSE a copy of the post-offer advertisement in line with Regulation 18(12) of SEBI (SAST) Regulations.

A key line in the disclosure is that the underlying transaction under the SPA remained unconsummated as per the post-offer advertisement. This is important context for investors tracking whether and when the change of control is completed.

Option to acquire residual shares at the same price

The post-offer advertisement also states that the acquirer holds an option to acquire additional residual shares held by sellers Narsimha Shiroor Kamath, Gautam Rasiklal Ashra, and Ajun Gautam Ashra. The option price mentioned is the same as the offer price, ₹299.00 per share.

This detail matters because it indicates the acquisition structure includes the possibility of picking up additional shares from identified sellers at a known price, subject to the conditions set out in the relevant agreements and disclosures.

Company disclosures beyond the open offer

Separately, Bliss GVS Pharma disclosed postal ballot results for two special resolutions appointing Mr. Vijayanarayanan Mahadevan (DIN: 06639177) and Mr. Deepak Rameshchandra Shah (DIN: 06954206) as Non-Executive Independent Directors, each for a five-year term.

The Draft Letter of Offer also lists Bliss GVS Pharma’s registered office as 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai, Maharashtra 400072, with contact details including telephone 022-42160000 and email info@blissgvs.com.

Key facts at a glance

Timeline: draft vs revised schedule

Market impact: what the open offer changes for shareholders

The open offer sets a defined cash exit option at ₹299 per share for public shareholders who choose to tender within the window. It also formalises the acquisition-related timelines and the process around eligibility and participation.

The disclosure that the SPA remained unconsummated, as stated in the post-offer advertisement, provides an additional data point for investors tracking transaction progress. Beyond that, the information provided is process-driven rather than performance-driven, with the primary investor implication being the availability of the tender route and the schedule.

Why the development is significant under SEBI SAST rules

Open offers in change-of-control situations are designed to give public shareholders an opportunity to exit at a regulated price discovered through prescribed methods. Here, the offer price was stated to be determined under Regulation 8(2) of the SAST Regulations.

The sequence of filings and updates also highlights how timelines can move after SEBI’s final observations, with the revised tendering period and identified date explicitly communicated. For investors, the clarity around dates, price, and share count is central, since participation depends on tendering within the specified window.

Conclusion

The Bliss GVS Pharma open offer connected to Anupam Rasayan’s May 2026 SPA has been communicated through the Draft Letter of Offer, revised schedules, and a post-offer advertisement filed with BSE by SBI Capital Markets. The open offer is for up to 26% at ₹299 per share, with a total consideration of ₹829.03 crore if fully accepted.

The revised tendering window ran from July 28 to August 10, 2026, with payment completion scheduled for August 24, 2026 as per the updated timeline, while the post-offer advertisement noted that the underlying SPA transaction remained unconsummated.